RBC puts Genentech at outperform

RBC Capital Markets analyst Jason Kantor rated Genentech, Inc. at outperform, average risk. Kantor sees Rituxan for the treatment of rheumatoid arthritis as a growth driver for this important Genentech and Biogen Idec franchise, with a market opportunity for Rituxan between $300 million and $500 million. Longer-term, Kantor believes Rituxan will show efficacy in lupus, multiple sclerosis and a variety of other autoimmune indications. Shares of the South San Francisco, Calif.-based biotherapeutic company were down $2.23, or 2.67%, at $81.35. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.